null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Palivizumab ELISA Kit (GXEL00062)

SKU GXEL00062
Product Type ELISA Kit
Assay Type Quantitative
Detection Method Colorimetric
Sensitivity 0.156 μg/ml
Range 0.31-5 μg/mL
Size 96T
Synonyms MEDI-493, 188039-54-5, MEDI493, SYNAGIS, Humanized MAb 1129, 1129
€880
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Palivizumab ELISA Kit

The Palivizumab ELISA Kit (SKU: GXEL00062) is a high-sensitivity quantitative ELISA assay developed for the quantitative measurement of Palivizumab in Plasma, Serum. The assay delivers a detection range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml and is read colorimetrically at 450 nm, making it well suited to quantitative research workflows.

Palivizumab (brand name Synagis) is a humanized IgG monoclonal antibody (mAb) manufactured by MedImmune with recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab directed against an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor and Cess. The human light chain sequence was derived from the constant domain of Cκ and the variable framework regions of the VL gene K104 with Jκ -4. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved the grafting of the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy chains and two light chains and has a molecular weight of approximately 148, 000 Daltons. Palivizumab was approved for medical use in 1998 but the indications for prophylaxis vary worldwide. Palivizumab is primarily indicated for the following conditions: prematurity (gestational age ≤ 35 weeks), bronchopulmonary dysplasia/chronic lung disease, hemodynamically significant congenital heart disease, and other serious medical disorders on an ad hoc basis. Infants with these medical conditions are at increased risk of more severe disease and more serious subsequent sequelae.

Supplied with pre-coated microplates and all core reagents, the Palivizumab ELISA Kit gives you a validated, ready-to-use solution for Palivizumab research. Get accurate and reliable results with the Palivizumab ELISA Kit from Assay Genie.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose